Company: PGEN
Filing Date: 2025-08-19
Form Type: S-3
Source: 0000950103-25-010472
Chunk: 14

Company: PRECIGEN, INC.
Filing Date: 2025-08-19
Form: S-3
Chunk 14
---
 or have the effect of discouraging a third party from attempting to acquire control of us.

<div align='center'>6

Special Note Regarding
Forward-Looking Statements</div>

This prospectus, the applicable prospectus supplement
and any free writing prospectus may contain forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995, which statements involve substantial risks and uncertainties. All statements, other than statements of historical facts,
included in this prospectus, including statements regarding our strategy; future events, including their outcome or timing; future operations;
future financial position; future revenue; projected costs; prospects; plans; objectives of management; and expected market growth, are
forward-looking statements. The words “aim”, “anticipate”, “assume”, “believe”, “continue”,
“could”, “due”, “estimate”, “expect”, “intend”, “may”, “plan”,
“objective”, “positioned”, “potential”, “predict”, “project”, “seek”,
“should”, “target”, “will”, “would”, and the negatives of these terms or similar expressions
are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These
statements may relate to, among other things: (i) the timeliness of regulatory approvals; (ii) our strategy and overall approach to our
business model, our efforts to realign our business, and our ability to exercise more control and ownership over the development process
and commercialization path; (iii) our ability to successfully enter new markets or develop additional product candidates, including the
expected timing and results of investigational studies and preclinical and clinical trials, whether with our collaborators or independently;
(iv) our ability to consistently manufacture our product candidates or, our products, if approved, on a timely basis or to establish agreements
with third-party manufacturers; (v) our ability to successfully enter into optimal strategic relationships directly or with our subsidiaries
and operating companies that we may form in the future; (vi) actual or anticipated variations in our operating results; (vii) actual or
anticipated fluctuations in competitors' or collaborators' operating results or changes in their respective growth rates; (viii) our cash
position; (ix) market conditions in our industry; (x) our expectations regarding the size of the patient populations amenable to treatment
with our product candidates; (xi) the volatility of our stock price; (xii) the ability, and the ability